search
Back to results

Treating Social Cognition With Theta Burst Stimulation; a Pilot Sudy (PilotTMS-COG)

Primary Purpose

Social Cognition in Patients With Schizophrenia

Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Active TBS
Sham TBS
Sponsored by
University Hospital, Caen
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Social Cognition in Patients With Schizophrenia focused on measuring theta burst stimulation, Social Cognition, MRSI, Schizophrenia, transcranial magnetic stimulation

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • with a diagnosis of schizophrenia or schizoaffective disorder (DSM-IV MINI R)
  • less than 20 years of disease duration
  • Having signed a written informed consent
  • LIS score > 15 or negative PANSS score > 15

Exclusion Criteria:

  • Any change in psychotropic drugs (antidepressants, antipsychotics or mood stabilizers) during the two months preceding the inclusion
  • Pregnant or breastfeeding women
  • Subjects with a neurological condition or with epilepsy
  • Subjects with a counter-indication to MRI or Transcranial stimulation (electronic or metal implants)
  • Subjects that refuse to wear earplugs during MRI

Sites / Locations

  • CHU de Caen - Centre EsquirolRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

No Intervention

Experimental

Active Comparator

Sham Comparator

Arm Label

Healthy subjects

TBS-MPC

TBS-CPDLF

TBS-Sham

Arm Description

Multimodal imaging data acquisitions Clinical data acquisitions

Intervention with active TBS aiming Medial Prefrontal Cortex in 6 patients with schizophrenia Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition Continuous actimetry acquisition

Intervention with active TBS aiming Dorsolateral Prefrontal Cortex in 6 patients with schizophrenia Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition Continuous actimetry acquisition

Intervention with Sham TBS in 8 patients with schizophrenia Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition Continuous actimetry acquisition

Outcomes

Primary Outcome Measures

V-LIS total score

Secondary Outcome Measures

GLX ratio
GLX (= Glutamine + Glutamate) ratio are measured in the DLPFC and in the MPC
P50 wave amplitude
Motor activity

Full Information

First Posted
May 4, 2015
Last Updated
July 19, 2017
Sponsor
University Hospital, Caen
search

1. Study Identification

Unique Protocol Identification Number
NCT02440867
Brief Title
Treating Social Cognition With Theta Burst Stimulation; a Pilot Sudy
Acronym
PilotTMS-COG
Official Title
Treating Social Cognition Impairments in Patients With Schizophrenia With Repetitive Transcranial Magnetic Stimulation (Theta-Burst; TBS); a Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
July 2017
Overall Recruitment Status
Unknown status
Study Start Date
May 2015 (undefined)
Primary Completion Date
December 2017 (Anticipated)
Study Completion Date
December 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Caen

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of the study is to test a new treatment of social cognition deficits in patients with schizophrenia or schizoaffective disorder by transcranial magnetic stimulation (theta-burst). The study will also identify clinical variables, cognitive and psychomotor most sensitive to treatment, to estimate the most sensitive treatment target, assess tolerance, to assess the impact of repetitive Transcranial Magnetic Stimulation (rTMS) on the brain a multimodal imaging study and compare the imaging variables (resting network, Diffusion Tensor Imaging, magnetic resonance spectroscopic imaging; MRSI) between patients before treatment and healthy subjects.
Detailed Description
The language understanding of other people is based on linguistic decoding mechanisms (phonological, semantic, syntactic ...) but also more on subtle mechanisms for the recognition of emotions and intentions. Interact with another one requires understanding its language but also to infer emotions and intentions. There are patients with schizophrenia suffering from social cognition disorders that impair social interactions; These patients often have difficulty in extracting the non-verbal emotional content of language and have difficulty inferring the thoughts and intentions of others. Recently, we have suggested a link between such deficits and the hypofunction of the medial prefrontal cortex. Transcranial magnetic stimulation is a noninvasive neuromodulation technique that increases or decreases the focal cortical excitability depending on stimulation parameters. This technique is now commonly used as a therapeutic tool. It has been tried with some success in patients with schizophrenia in some indications: To reduce the auditory verbal hallucinations stimulating the temporal cortex More rarely, to reduce the negative symptoms stimulating the dorsolateral prefrontal cortex So far, the medial prefrontal cortex was not considered as a possible target as the scalp to cortex distance prevent from using conventional stimulation coils. Recently new coils have been developed that permit stimulation of deeper cortical regions. We hypothesize that the use of transcranial magnetic stimulation with a theta burst intermittent protocol known to increase the cortical excitability and aiming the medial prefrontal cortex with a special antenna will improve social interaction capabilities of schizophrenic patients. This ambitious and innovative assumption shall be first supported by a study of feasibility which is the subject of this trial. Moreover, changes in the anatomical and functional connectivity, in brain metabolism and in cortical excitability will be observed after stimulation thanks to a multimodal imaging and the study of P50 wave. In this pilot study, involving 20 patients, we plan to assess the social cognition deficits before and after 10 sessions of magnetic stimulation (2 sessions per day for 5 consecutive days) using a neuronavigation system and Magstim® stimulator. In order to assess the feasibility and specificity of the stimulation of medial prefrontal cortex (MPC), the effects of this treatment will be compared to the effects of the same treatment aiming the dorsolateral prefrontal cortex (DLPFC), also involved in aspects of negative symptoms of schizophrenia, and placebo effects induced by sham stimulation (using a sham coil). The recording of the P50 wave will be just before and after the 1st session and just after the last stimulation session. An MRI anatomical, functional and spectroscopic be performed before and 30 days after the treatment. A control group of twenty healthy subjects will perform the same MRI acquisitions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Social Cognition in Patients With Schizophrenia
Keywords
theta burst stimulation, Social Cognition, MRSI, Schizophrenia, transcranial magnetic stimulation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Healthy subjects
Arm Type
No Intervention
Arm Description
Multimodal imaging data acquisitions Clinical data acquisitions
Arm Title
TBS-MPC
Arm Type
Experimental
Arm Description
Intervention with active TBS aiming Medial Prefrontal Cortex in 6 patients with schizophrenia Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition Continuous actimetry acquisition
Arm Title
TBS-CPDLF
Arm Type
Active Comparator
Arm Description
Intervention with active TBS aiming Dorsolateral Prefrontal Cortex in 6 patients with schizophrenia Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition Continuous actimetry acquisition
Arm Title
TBS-Sham
Arm Type
Sham Comparator
Arm Description
Intervention with Sham TBS in 8 patients with schizophrenia Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition Continuous actimetry acquisition
Intervention Type
Device
Intervention Name(s)
Active TBS
Intervention Description
Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
Intervention Type
Device
Intervention Name(s)
Sham TBS
Intervention Description
Sham stimulation
Primary Outcome Measure Information:
Title
V-LIS total score
Time Frame
change from baseline in V-LIS total score compared to 30 days after the end of the treatment
Secondary Outcome Measure Information:
Title
GLX ratio
Description
GLX (= Glutamine + Glutamate) ratio are measured in the DLPFC and in the MPC
Time Frame
change in baseline GLX ratio measured in MRSI compared to 30 days after the end of the treatment
Title
P50 wave amplitude
Time Frame
change in baseline P50 amplitude compared to immediately after the end of the treatment
Title
Motor activity
Time Frame
change in baseline motor activity measured with an actimeter compared to 30 days after the end of the treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: with a diagnosis of schizophrenia or schizoaffective disorder (DSM-IV MINI R) less than 20 years of disease duration Having signed a written informed consent LIS score > 15 or negative PANSS score > 15 Exclusion Criteria: Any change in psychotropic drugs (antidepressants, antipsychotics or mood stabilizers) during the two months preceding the inclusion Pregnant or breastfeeding women Subjects with a neurological condition or with epilepsy Subjects with a counter-indication to MRI or Transcranial stimulation (electronic or metal implants) Subjects that refuse to wear earplugs during MRI
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Clement Nathou, MD
Phone
(0)231065018
Ext
+33
Email
nathou@chu-caen.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Sonia Dollfus, MD, PhD
Phone
(0)231065018
Ext
+33
Email
dollfus@chu-caen.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clément Nathou, MD
Organizational Affiliation
University Hospital, Caen
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU de Caen - Centre Esquirol
City
Caen
ZIP/Postal Code
14033
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Clément Nathou, Dr.
Phone
+33231065018
Email
nathou-c@chu-caen.fr

12. IPD Sharing Statement

Learn more about this trial

Treating Social Cognition With Theta Burst Stimulation; a Pilot Sudy

We'll reach out to this number within 24 hrs